Drug delivery system to increase bioavailability

1. A drug delivery system comprising:

a lubricant comprising a stearate, stearic acid, talc, glyceryl behenate, lauryl sulfates, oleates, or DL-leucine;

a binder comprising a saccharide, a gelatin, pregelatinized starches, hydroxypropylcellulose or cellulosic ethers;

lactose;

polyvinylpyrrolidone;

a copolymer of polyvinylpyrrolidone and vinyl acetate;

a silicon dioxide present in an amount of from about 2 weight percent to about 30 weight percent;

and a stearyl fumarate or a stearate, wherein the total components equal 100 weight percent, wherein the silicon dioxide increases the bioavailability of biopharmaceutic class II, III, or IV active agents.

2. The drug delivery system of claim 1 , wherein the silicon dioxide is colloidal silicon dioxide.

3. The drug delivery system of claim 1 , wherein the cellulose is microcrystalline cellulose.

4. The drug delivery system of claim 2 , wherein the lubricant is present in an amount of from about 0.5 weight percent to about 6 weight percent.

5. The drug delivery system of claim 3 , wherein the lubricant is present in an amount of from about 0.5 weight percent to about 6 weight percent.

6. The drug delivery system of claim 2 , wherein the binder is present in an amount of from about 20 weight percent to about 70 weight percent.

7. The drug delivery system of claim 3 , wherein the binder is present in an amount of from about 20 weight percent to about 70 weight percent.

8. The drug delivery system of claim 2 , wherein the lactose is present in an amount of from about 10 weight percent to about 40 weight percent.

9. The drug delivery system of claim 3 , wherein the lactose is present in an amount of from about 10 weight percent to about 40 weight percent.

10. The drug delivery system of claim 2 , wherein the polyvinyl pyrrolidone is present in an amount of from about 5 weight percent to about 25 weight percent.

11. The drug delivery system of claim 3 , wherein the polyvinyl pyrrolidone is present in an amount of from about 5 weight percent to about 25 weight percent.

12. The drug delivery system of claim 2 , wherein the copolymer of polyvinylpyrrolidone and vinyl acetate is present in an amount of from about 2 weight percent to about 10 weight percent.

13. The drug delivery system of claim 3 , wherein the copolymer of polyvinylpyrrolidone and vinyl acetate is present in an amount of from about 2 weight percent to about 10 weight percent.

14. The drug delivery system of claim 2 , wherein the stearyl fumarate or stearate is present in an amount of from about 0.25 weight percent to about 7.5 weight percent.

15. The drug delivery system of claim 3 , wherein the stearyl fumarate or stearate is present in an amount of from about 0.25 weight percent to about 7.5 weight percent.

16. The drug delivery system of claim 2 , wherein the polyvinyl pyrrolidone is present in an amount of from about 5 weight percent to about 12 weight percent and the copolymer of polyvinylpyrrolidone and vinyl acetate is present in an amount of from about 0.5 weight percent to about 5 weight percent.

17. The drug delivery system of claim 3 , wherein the polyvinyl pyrrolidone is present in an amount of from about 5 weight percent to about 12 weight percent and the copolymer of polyvinylpyrrolidone and vinyl acetate is present in an amount of from about 0.5 weight percent to about 5 weight percent.

18. The drug delivery system of claim 2 , further comprising a polyoxyethylene-polyoxypropylene copolymer.

19. The drug delivery system of claim 3 , further comprising a polyoxyethylene-polyoxypropylene copolymer.

20. A drug delivery system comprising:

a lubricant comprising a stearate, stearic acid, talc, glyceryl behenate, lauryl sulfates, oleates, or DL-leucine;

a binder comprising a saccharide, a gelatin, pregelatinized starches, hydroxypropylcellulose or cellulosic ethers;

lactose;

polyvinylpyrrolidone;

a copolymer of polyvinylpyrrolidone and vinyl acetate;

a silicon dioxide;

and a stearyl fumarate or a stearate, wherein the polyvinyl pyrrolidone is present in an amount of from about 5 weight percent to about 12 weight percent, the copolymer of polyvinylpyrrolidone and vinyl acetate is present in an amount of from about 0.5 weight percent to about 5 weight percent and the silicon dioxide is present in an amount of from about 2 weight percent to about 30 weight percent, wherein the total components equal 100 weight percent, and wherein the silicon dioxide increases the bioavailability of biopharmaceutic class II, III, or IV active agents.